8.3 Antimicrobial Stewardship Principles & Interventions
Key Takeaways
- The CDC Core Elements of Hospital Antibiotic Stewardship Programs establish seven essential structural components: Hospital Leadership Commitment, Accountability, Pharmacy Expertise, Action, Tracking, Reporting, and Education.
- Prospective Audit and Feedback (PAF) and Pre-authorization (Formulary Restriction) represent the two core active stewardship strategies; PAF allows initial empirical therapy followed by expert review at 48-72 hours, preserving clinician autonomy.
- Mandatory antibiotic time-outs at 48-72 hours require clinicians to reassess antimicrobial therapy based on culture results, clinical response, and de-escalation opportunities.
- IV-to-oral (IV-to-PO) conversion protocols reduce hospital length of stay, central line-associated bloodstream infection (CLABSI) risk, and drug costs by transitioning patients with functional gastrointestinal tracts to highly bioavailable oral agents.
- Cumulative antibiograms present regional or facility-specific antimicrobial susceptibility percentages compiled annually according to CLSI M39 guidelines, guiding empirical antibiotic selection.
8.3 Antimicrobial Stewardship Principles & Interventions
Quick Answer: Antimicrobial Stewardship Programs (ASPs) optimize clinical outcomes while minimizing unintended consequences of antimicrobial use, such as toxicity, selection of resistant organisms, and Clostridioides difficile infection. Anchored by the CDC Core Elements of Hospital Antibiotic Stewardship Programs, effective ASPs implement core interventions including Prospective Audit and Feedback (PAF), Pre-authorization, 48-72 Hour Antibiotic Time-Outs, IV-to-Oral Conversions, and annual facility Antibiograms prepared according to CLSI M39 standards.
Antimicrobial resistance (AMR) is a major global public health threat. Misuse and overuse of antimicrobials drive the emergence of multidrug-resistant organisms (MDROs), such as Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE), Carbapenem-Resistant Enterobacterales (CRE), and multidrug-resistant Pseudomonas aeruginosa. Antimicrobial stewardship works hand-in-hand with infection prevention to preserve efficacy of existing drugs.
CDC Core Elements of Hospital Antibiotic Stewardship Programs
The CDC outlines seven essential structural components that form the framework for successful hospital stewardship programs:
- Hospital Leadership Commitment: Dedicating necessary human, financial, and information technology resources. This includes providing salary support for ASP co-directors and supporting stewardship IT tools.
- Accountability: Appointing a single physician leader responsible for program outcomes. Co-leadership models pairing an Infectious Diseases physician with a clinical pharmacist are considered best practice.
- Pharmacy Expertise: Appointing a dedicated lead pharmacist, ideally formal board-certified or residency-trained in Infectious Diseases, as co-leader.
- Action: Implementing evidence-based interventions to improve antibiotic prescribing practice (e.g., PAF, pre-authorization, order sets).
- Tracking: Monitoring antibiotic prescribing patterns and outcome metrics, such as Days of Therapy (DOT) per 1,000 patient-days, Standardized Antimicrobial Administration Ratio (SAAR) via NHSN, C. difficile rates, and resistance trends.
- Reporting: Regularly sharing prescribing and resistance data with prescribers, facility leadership, and nursing staff.
- Education: Providing ongoing education to prescribers, pharmacists, nurses, and patients regarding optimal antimicrobial use and resistance hazards.
Core Active Stewardship Interventions
Stewardship programs implement primary active interventions to optimize therapy. The two foundational active strategies are Prospective Audit and Feedback (PAF) and Pre-authorization (Formulary Restriction).
| Intervention Strategy | Operational Workflow | Key Advantages | Potential Limitations |
|---|---|---|---|
| Prospective Audit and Feedback (PAF) | Stewardship team reviews active antimicrobial orders after 48-72 hours of therapy and provides real-time recommendations to prescribers to de-escalate, adjust, or discontinue. | Maintains prescriber autonomy, provides direct educational touchpoints, addresses therapy when full culture results are finalized. | Requires dedicated daily FTE personnel, recommendations may be rejected by treating physicians. |
| Pre-authorization (Formulary Restriction) | Requires prescribers to obtain approval from the ASP team or ID specialist before restricted broad-spectrum antimicrobials (e.g., meropenem, daptomycin) are dispensed. | Immediately reduces inappropriate initiation of targeted broad-spectrum drugs, controls pharmacy costs, prevents empiric overuse. | Can cause administration delays, creates prescriber friction, may lead to overuse of non-restricted agents ("squeeze the balloon" effect). |
| Antibiotic Time-Outs (48-72 Hours) | Mandatory provider reassessment of antimicrobial indication, culture results, and clinical status at 48 to 72 hours post-initiation. | Simple, scalable routine workflow embedded into Electronic Health Records (EHR), encourages provider self-reflection. | Passive intervention if not reinforced by clinical decision support or ASP follow-up. |
| IV-to-Oral (PO) Conversion | Automatic or protocol-driven transition from intravenous to oral administration for highly bioavailable agents once patient criteria are met. | Reduces line-associated infection risks (CLABSI), shortens length of stay, lowers administration costs and patient discomfort. | Requires patient to have a functioning GI tract and clinical stability. |
Clinical Criteria for IV-to-Oral (PO) Step-Down Conversion
Transitioning patients from IV to oral therapy is a high-impact safety and efficiency intervention. Candidates for IV-to-PO conversion must meet specific clinical criteria:
- Functioning Gastrointestinal Tract: Patient is tolerating oral diet, oral medications, or enteral tube feedings without severe nausea, vomiting, active GI bleeding, or malabsorption.
- Hemodynamic Stability: Vital signs are stable, patient is afebrile or improving, and no continuous vasopressor support is required.
- Clinical Improvement: White blood cell count (WBC) is normalizing, and clinical signs of infection (e.g., cough, dyspnea, localized erythema) are resolving.
- Highly Bioavailable Antimicrobials: Selection of oral agents with near-equivalent oral bioavailability (e.g., fluoroquinolones [ciprofloxacin, levofloxacin], linezolid, metronidazole, fluconazole, trimethoprim-sulfamethoxazole, doxycycline).
Antibiograms: Development, Standards, and Clinical Interpretation
A cumulative Antibiogram is an annual report displaying the overall percentage of isolated microorganisms susceptible to tested antimicrobial agents within a specific healthcare facility.
CLSI M39 Compilation Guidelines
The Clinical and Laboratory Standards Institute (CLSI M39 document) defines standard methodologies for preparing antibiograms to ensure statistical reliability:
- First Isolate Per Patient: Include only the first isolate of a given species per patient during the analysis period (e.g., 1 year), regardless of specimen body site or antimicrobial susceptibility profile. This eliminates bias caused by repeated cultures from chronically infected patients.
- Minimum Isolate Volume: Report susceptibility percentages only for species with at least 30 isolates evaluated during the time period. Statistical percentages derived from fewer than 30 isolates are unreliable and misleading.
- Diagnostic Isolates Only: Include diagnostic clinical isolates; exclude surveillance screening cultures (e.g., MRSA nasal swabs or VRE rectal swabs).
- Annual Frequency: Analyze and publish the antibiogram at least annually.
Sample Antibiogram Table & Interpretation
The table below illustrates a representative facility-level antibiogram matrix for Gram-negative organisms:
| Organism (Isolate Count) | Ampicillin/Sulbactam | Cefepime | Piperacillin/Tazobactam | Meropenem | Ciprofloxacin | Gentamicin |
|---|---|---|---|---|---|---|
| Escherichia coli (n = 450) | 58% | 88% | 94% | 99% | 72% | 91% |
| Klebsiella pneumoniae (n = 180) | 70% | 91% | 93% | 98% | 85% | 94% |
| Pseudomonas aeruginosa (n = 95) | 0% (R) | 84% | 86% | 89% | 78% | 88% |
Legend: Values represent % Susceptible. (R) = Intrinsic Resistance.
Clinical Decision-Making from Antibiograms
- Empiric Therapy Selection: Prescribers use antibiograms to choose initial empiric therapy before culture results return. For severe sepsis or life-threatening infections, an agent with > 90% susceptibility coverage is generally selected.
- Formulary Decisions: ASP teams use longitudinal antibiogram trends to guide formulary decisions and track community/facility resistance progression (e.g., tracking ESBL rates in E. coli).
According to the CDC Core Elements of Hospital Antibiotic Stewardship Programs, which structural element focuses on monitoring Days of Therapy (DOT), Standardized Antimicrobial Administration Ratios (SAAR), and C. difficile incidence rates?
What is a primary operational advantage of Prospective Audit and Feedback (PAF) compared to Pre-authorization (Formulary Restriction)?
According to CLSI M39 guidelines for cumulative antibiogram preparation, which rule must be followed to ensure statistical validity and prevent data skewing?
A hospitalized patient receiving IV levofloxacin for community-acquired pneumonia has been afebrile for 24 hours, has a normalizing white blood cell count, and is consuming a regular oral diet. The stewardship pharmacist recommends converting to oral levofloxacin. What is the primary clinical rationale for this IV-to-oral step-down?